Biotechnology in healthcare is the use of living systems — cells, proteins, nucleic acids, and engineered organisms — to develop medicines, diagnostics, and therapeutic techniques. Where traditional pharmaceutical chemistry synthesises small molecules, biotechnology produces large, complex molecules in living cells, or modifies biological material directly, as in cell and gene therapy.
The distinction matters practically as well as scientifically. Biological products differ from small molecules in how they are discovered, how they are manufactured, how they are administered, how the immune system responds to them, and how regulators evaluate them.
What Distinguishes a Biologic from a Small-Molecule Drug
A small-molecule medicine is typically a compact chemical structure, made by defined synthetic steps, reproducible to an identical specification, and often taken orally. Its structure can be fully characterized by analytical chemistry.
A biologic is orders of magnitude larger, with a three-dimensional structure and, frequently, attached sugar chains that affect how it behaves. It is produced by living cells engineered to express it, purified through multi-step processes, and usually administered by injection or infusion because digestion would destroy it. Because production depends on living systems, small changes in the process can alter the product, and full characterization by analysis alone is not possible.
Two consequences follow. First, biologics can be immunogenic: the immune system may recognise them as foreign and generate antibodies that reduce efficacy or cause reactions, so immunogenicity is assessed throughout development. Second, generic-style duplication is not achievable, which is why highly similar versions are called biosimilars and are approved through a tailored comparability route rather than simple bioequivalence.
The Main Categories of Biotechnology Medicine
Monoclonal Antibodies
Monoclonal antibodies are laboratory-produced proteins designed to bind a single specific target — a receptor on a cell surface, a circulating signalling molecule, or a feature of a pathogen. Their selectivity allows precise interference with a defined biological pathway. They are used across oncology, immunology, inflammatory disease, and infectious disease. Engineered variants include antibody-drug conjugates, which link an antibody to a cytotoxic payload so that the toxic agent is delivered preferentially to target cells, and bispecific antibodies, which bind two targets simultaneously.
Therapeutic Proteins and Enzymes
Recombinant proteins replace or supplement a protein the body cannot produce in sufficient quantity or functional form. Recombinant insulin, clotting factors for haemophilia, and enzyme replacement therapies for inherited metabolic disorders belong to this category, which represents some of the earliest and most established biotechnology medicine.
Vaccines
Vaccines train the immune system to recognise a pathogen. Biotechnology has expanded the range of platforms available, including recombinant protein subunit vaccines, viral vector vaccines, and messenger RNA vaccines, which deliver instructions for cells to produce an antigen rather than delivering the antigen itself.
Nucleic Acid Therapeutics
These act on the genetic instructions inside cells rather than on proteins. Antisense oligonucleotides and small interfering RNA can reduce production of a specific protein; messenger RNA can direct production of a desired one. Delivery — getting nucleic acids into the right cells intact — is the central technical challenge, addressed through chemical modification and delivery systems such as lipid nanoparticles.
Gene Therapy and Gene Editing
Gene therapy aims to treat disease by introducing, replacing, or altering genetic material, often using engineered viral vectors to deliver a functional copy of a gene. Gene editing technologies, including CRISPR-based systems, allow targeted modification of sequences within a genome. These approaches are most advanced in inherited single-gene disorders and certain blood and eye conditions. Key considerations include durability of effect, immune responses to vectors, the possibility of off-target edits, and the need for long-term follow-up.
Cell Therapy
Cell therapies use living cells as the treatment. CAR T-cell therapy is the most established example: a patient's own T cells are collected, genetically engineered to recognise a target on cancer cells, expanded, and returned to the patient. Because the product is made from individual patients' cells, manufacturing is complex, time-critical, and difficult to scale, and serious immune-related toxicities require specialist management.
Diagnostics and Research Tools
Biotechnology also underpins diagnostics: molecular tests such as PCR, next-generation sequencing used in oncology and inherited disease, and companion diagnostics that identify patients likely to benefit from a specific targeted therapy. Research tools, including engineered cell lines and organoids, support discovery across the sector.
How Biotechnology Companies Work
Origins
Biotechnology firms frequently originate in academic research, founded around a specific mechanism, target, or enabling platform technology. Platform companies aim to apply one technical approach — an antibody discovery method, a delivery system, an editing technology — across multiple diseases rather than pursuing a single product.
Funding
Because revenue typically arrives long after the science, biotechnology depends on external funding: venture capital, public equity markets, licensing deals and milestone payments from larger pharmaceutical partners, government and charitable research grants, and public-private partnerships. Funding availability shapes which diseases attract development attention, and conditions with small patient populations or limited ability to pay have historically been under-served, prompting orphan drug incentives and non-profit product development partnerships.
Partnering and Consolidation
A common pattern is for a smaller company to advance a candidate through early clinical testing and then partner with, license to, or be acquired by a larger firm with the capacity to run confirmatory trials, navigate multiple regulatory systems, and manufacture and distribute at scale. This division of labour concentrates early scientific risk in smaller organizations and late-stage execution in larger ones.
Biomanufacturing
Manufacturing is a defining constraint in biotechnology. Production typically involves engineered cell lines grown in bioreactors under tightly controlled conditions, followed by multi-step purification, formulation, and fill-finish. Processes operate under Good Manufacturing Practice and are subject to regulatory inspection.
Because the process defines the product, changes to it — a new facility, a modified cell line, a scale increase — require comparability studies to demonstrate that the product remains equivalent. Many biologics require cold chain storage and distribution, and some cell therapies must reach the patient within a narrow time window. Capacity constraints in specialised manufacturing are a recognised bottleneck for advanced therapies.
Regulation of Biological Products
Biologics are regulated under frameworks adapted to their complexity. In the United States, most are authorized through a Biologics License Application; in the European Union, biotechnology-derived products must use the centralised procedure administered by the EMA, and advanced therapy medicinal products — gene therapies, cell therapies, and tissue-engineered products — are assessed with input from a dedicated specialist committee.
Regulatory expectations reflect the modality. Immunogenicity assessment is standard. Manufacturing comparability evidence carries unusual weight. Gene and cell therapies commonly carry long-term follow-up obligations extending years beyond treatment, given the durability of the intervention and theoretical late risks. Biosimilars are approved on the basis of demonstrated similarity to a reference product across analytical, functional, pharmacokinetic, and targeted clinical comparisons.
Challenges and Open Questions
- Cost and access. Complex manufacturing and small target populations contribute to high prices, creating difficult reimbursement decisions and marked global inequity in availability.
- Delivery. Getting large molecules or genetic material to the right tissue remains a central technical limitation, particularly for targets in the central nervous system.
- Durability and long-term safety. One-time therapies raise questions about how long benefit lasts and what late effects may emerge, answerable only through extended follow-up.
- Manufacturing scale. Personalised cell therapies are difficult to produce at population scale; allogeneic "off-the-shelf" approaches are being investigated to address this.
- Ethics and governance. Gene editing raises questions about the boundary between treatment and enhancement, and heritable germline editing is subject to prohibition or strict restriction in most jurisdictions.
Sources
- U.S. Food and Drug Administration — Center for Biologics Evaluation and Research; biosimilar and advanced therapy guidance
- European Medicines Agency — advanced therapy medicinal products; biosimilar guidelines; centralised procedure
- U.S. National Institutes of Health — gene therapy and biotechnology research resources
- World Health Organization — biological standardization and prequalification
- International Council for Harmonisation — quality guidelines for biotechnological products
